Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K12 | Q12852 | 8/20 | 0.40 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.38 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.38 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.38 |
| ▸ | MAP3K7 | O43318 | 2/20 | 0.36 |
| ▸ | MAP3K13 | O43283 | 1/20 | 0.36 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.36 |
| ▸ | PIK3R1 | P27986 | 6/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 6/20 | 0.36 |
| ▸ | DLK1 | P80370 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21997512 | 1.00 | MAP3K12 (0.40) | MAP3K12APOBEC3AAPOBEC3GMCHR1MAP3K7 | |
| SCHEMBL21997412 | 0.78 | APOBEC3A (0.42) | APOBEC3AAPOBEC3G | |
| SCHEMBL22835228 | 0.77 | MAP3K12 (0.42) | MAP3K12MCHR1MAP3K13PIK3R1PIK3CA | |
| SCHEMBL22835973 | 0.77 | MAP3K12 (0.42) | MAP3K12MCHR1MAP3K13PIK3R1PIK3CA | |
| SCHEMBL21997978 | 0.77 | APOBEC3A (0.41) | APOBEC3AAPOBEC3G | |
| SCHEMBL23945834 | 0.76 | IRAK4 (0.46) | NTRK1 | |
| SCHEMBL21997814 | 0.76 | IRAK4 (0.46) | NTRK1 | |
| SCHEMBL21996976 | 0.76 | IRAK4 (0.46) | NTRK1 | |
| SCHEMBL21996677 | 0.76 | IRAK4 (0.46) | NTRK1 | |
| SCHEMBL25987203 | 0.76 | IRAK4 (0.46) | NTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239777-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-07-18 | — | — | US | disclosed |
| US-20240131016-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-04-25 | — | — | US | disclosed |
| US-20230416242-A1 | DOUBLE DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-12-28 | — | — | US | disclosed |
| US-20230406866-A1 | CRYSTALLINE FORMS OF IRAK DEGRADERS | KYMERA THERAPEUTICS, INC. | 2023-12-21 | — | — | US | disclosed |
| US-11807636-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| EP-4259128-A1 | IRAK DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2023-10-18 | — | — | EP | disclosed |
| US-11779578-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-20230250110-A1 | DEUTERATED IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-08-10 | — | — | US | disclosed |
| US-11707457-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-20230122219-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-04-20 | — | — | US | disclosed |
| US-20230096599-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-03-30 | — | — | US | disclosed |
| EP-4100004-A1 | IRAK DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2022-12-14 | — | — | EP | disclosed |
| WO-2022125790-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2022-06-16 | — | — | WO | disclosed |
| US-11352350-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-20210323952-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2021-10-21 | — | — | US | disclosed |
| EP-3886904-A1 | IRAK DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2021-10-06 | — | — | EP | disclosed |
| US-11117889-B1 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2021-09-14 | — | — | US | disclosed |
| WO-2021158634-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2021-08-12 | — | — | WO | disclosed |
| US-20210228562-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2021-07-29 | — | — | US | disclosed |
| WO-2020113233-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2020-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230416242-A1 | DOUBLE DEGRADERS AND USES THEREOF | DCXR, IDUA, GUSB | MAP3K12 4564/4885APOBEC3A 19/4885APOBEC3G 11/4885 |
| US-20240131016-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | MAP3K12 178/4885APOBEC3A 219/4885APOBEC3G 151/4885 |
| US-11117889-B1 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | MAP3K12 178/4885APOBEC3A 219/4885APOBEC3G 151/4885 |
| US-11352350-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | MAP3K12 178/4885APOBEC3A 219/4885APOBEC3G 151/4885 |
| US-20210323952-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | MAP3K12 178/4885APOBEC3A 219/4885APOBEC3G 151/4885 |
| US-20230406866-A1 | CRYSTALLINE FORMS OF IRAK DEGRADERS | IRAK1, IRAK2, IRAK4 | MAP3K12 369/4885APOBEC3A 2924/4885APOBEC3G 3508/4885 |
| US-20240239777-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | MAP3K12 178/4885APOBEC3A 219/4885APOBEC3G 151/4885 |
| US-20230096599-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | MAP3K12 178/4885APOBEC3A 219/4885APOBEC3G 151/4885 |
| US-11807636-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | MAP3K12 178/4885APOBEC3A 219/4885APOBEC3G 151/4885 |
| US-20230122219-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | MAP3K12 178/4885APOBEC3A 219/4885APOBEC3G 151/4885 |
| US-20210228562-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | MAP3K12 178/4885APOBEC3A 219/4885APOBEC3G 151/4885 |
| US-11779578-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | MAP3K12 178/4885APOBEC3A 219/4885APOBEC3G 151/4885 |
| US-20230250110-A1 | DEUTERATED IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | MAP3K12 152/4885APOBEC3A 183/4885APOBEC3G 90/4885 |
| US-11707457-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | MAP3K12 178/4885APOBEC3A 219/4885APOBEC3G 151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.